-
Signature
-
/s/ Debra E. Levin, attorney-in-fact
-
Stock symbol
-
BLCO
-
Transactions as of
-
May 5, 2022
-
Transactions value $
-
$0
-
Form type
-
4
-
Date filed
-
5/9/2022, 06:46 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
BLCO |
Common Shares, No Par Value |
Award |
$0 |
+83.3K |
|
$0.00 |
83.3K |
May 5, 2022 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
BLCO |
Non-Qualified Stock Options (right to purchase) |
Award |
$0 |
+330K |
|
$0.00 |
330K |
May 5, 2022 |
Common Shares, No Par Value |
330K |
$18.00 |
Direct |
F2, F3, F4 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
The Reporting Person's title as an officer of the Issuer is Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals.